Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | FASN | P49327 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28312550 | 1.00 | RECQL (0.63) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL11969437 | 0.98 | RECQL (0.61) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL28313549 | 0.94 | RECQL (0.57) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL20178173 | 0.94 | RECQL (0.57) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL30072373 | 0.89 | HPGD (0.56) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL2677323 | 0.87 | RECQL (0.59) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL1372881 | 0.86 | RECQL (0.62) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL3122976 | 0.85 | RECQL (0.56) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL5423821 | 0.85 | RECQL (0.56) | RECQLPOLBALDH1A1KDM4ETSHR | |
| SCHEMBL3550415 | 0.85 | RECQL (0.56) | RECQLPOLBALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | RECQL 763/4885POLB 708/4885ALDH1A1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.